The Marburg virus (MARV) belongs to the order Mononegavirales, the family Filoviridae, and the genus Marburgvirus of viruses that cause hemorrhagic fever [1]. There was the first report of the Marburg virus in 1967 [2]. There were outbreaks of the disease in Marburg and Frankfurt in Germany and Belgrade in the Yugoslav Republic that year [3]. In Angola, approximately 252 people were infected with MARV in 2004, and 90 % of the patients died [4]. The recent outbreak in Tanzania and Guinea declared on February 2023, started new challenges [5]. In 2018, MARV was added to the Priority Disease List [6], and humans are similarly affected by MARV to those who are infected with the more well-known Ebola virus (EBOV) [7]. In addition, MARV is a member of the group of negative-strand RNA viruses that are not segmented [6]. The MARV encoded seven structural proteins such as nucleoprotein (NP), RNA-directed RNA polymerase L (L), polymerase cofactor VP35 (VP35), minor nucleoprotein (VP30), membrane-associated protein VP24, matrix protein (VP40), and envelope glycoprotein (GP) [8]. MARV like many other families of viruses binds to host cells through the use of surface factors such as GP that facilitate to entry of the virus [9]. Currently, there is no approved vaccine or drug treatment for MARV. As a result of the emerging virus being vaccinated with a recent vaccine, the Chimpanzee adenovirus serotype 3 vector (cAd3-Marburg), 90 % of the participants were protected against GP with antibody responses at four weeks following a single vaccination [10]. In addition, the MARV vaccine with significant efficiency is the MARV DNA plasmid vaccine (VRC-MARDNA025-00-VP) [11]. To progress the vaccine treatment, the immunoinformatics approaches aid in estimating the novel vaccine against MARV. In recent years, immunoinformatics has become a brand-new discipline that investigates immunological data and the tools created to handle this data. The immunoinformatics method is a functional technique that can anticipate the polypeptide vaccine [12]. The goal of the multi-epitope vaccines is to decrease the restriction caused by MHC restriction into a single unit while simultaneously inducing a variety of immune responses to incorporate the antigens [13]. This innovative method was used to create a vaccination against several infections, such as virus (SARS-CoV-2) [14], bacteria (Burkholderia pseudomallei) [15], and fungi (Candida tropicalis) [16]. Due to these numerous benefits, many research investigations have been conducted to investigate the effectiveness of this novel type of vaccination. These studies revealed considerable activation at the humoral and cellular arms of the immune system against Crimean–Congo Hemorrhagic Fever Virus [17] and Leishmania Parasite [18]. In this study, we focused on the glycoprotein and predicted the epitopes that are conserved regions of the glycoprotein. In addition, epitopes can stimulate humeral and cell-mediated responses, this potential epitope was designed with linkers and adjuvants that were assessed computationally for their structural, physicochemical, and immunological properties to be a candidate as a putative solution against MARV. The workflow of the research is demonstrated in Fig. 1.